Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology
Retrieved on:
Saturday, June 4, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acceleration, Glucocorticoid, Osteoporosis, Steroid, EULAR, Weight gain, CORT, PMR, Liver, Disease, Medication, Tissue (biology), Insulin resistance, Autoimmunity, Cardiovascular disease, Prednisone, Brain, Endocrinology, Patient, 2021 Essex County Council election, Diabetes, Mouse, Autoimmune disease, CSO, Prednisolone, Clinical trial, Tissue, Skin, Polymyalgia rheumatica, Hypertension, Pharmaceutical industry, Rheumatology
Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica at the 2022 Annual European Congress of Rheumatology (EULAR 2022).
Key Points:
- Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica at the 2022 Annual European Congress of Rheumatology (EULAR 2022).
- Researchers studied the ability of Sparrows therapeutic candidate SPI-62, a HSD-1 inhibitor, to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse.
- SPI-47, a fixed-dose-combination of SPI-62 and prednisolone, is in clinical development for autoimmune and inflammatory diseases.
- An effective glucocorticoid with fewer side effects would be a boon for patients, said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals.